Researchers identify markers of enzalutamide resistance in prostate cancer
February 12th 2024"We hope that this study will build a roadmap to personalized therapeutic advice for patients with advanced prostate cancer and potentially will improve their quality of life and outcomes," says Antonina Mitrofanova, PhD.
What to know when considering an ancillary service in a urology practice
February 6th 2024"At MIU, we host many ancillary services, including complete ultrasound services, UroCuff, urodynamics, PTNS [percutaneous tibial nerve stimulation], full laboratory and pathology services, Xofigo [radium-223]," says Jason M. Hafron, MD.
Investigators compare costs for surgical treatments of BPH
February 4th 2024"I think, importantly, when we look at comparing BPH surgical intervention options, we should not only factor in clinical outcomes and clinical differences, but also in the setting of our current health system, cost is becoming increasingly important," says Kevin M. Wymer, MD.
Dr. Sankin and Dr. Aboumohamed on advances in urologic cancer care
February 3rd 2024"There's just a lot of active trials being studied, and hopefully, in the next 5 or 10 years, we'll see another handful of agents get approved and really start to make some headway in [NMIBC]," says Alexander I. Sankin, MD.
Dr. Agarwal on data from the phase 3 CONTACT-2 trial in mCRPC
January 31st 2024“If you put everything together, the cabo/atezo combination statistically significantly improved the progression-free survival and reduced the risk of progression or death by 35% in a patient population with very poor prognosis,” says Neeraj Agarwal, MD, FACSO.
Dr. Lowentritt on the impact of flotufolastat F 18 in prostate cancer management
January 27th 2024"What we saw was it that there were a significant number of patients that did change their management based on the findings. Of those patients, 88% of them changed because of a positive test," says Benjamin H. Lowentritt, MD, FACS.
Dr. Nizam on EV following maintenance avelumab in advanced UC
January 26th 2024"The key end points were observed response rate in the overall cohort, progression-free and overall survival from EV start in the overall cohort, and as an exploratory end point, overall survival from platinum-based chemotherapy start in the overall cohort," says Amanda Nizam, MD.